Pharmacoeconomic analysis of infertility treatment in women with a suboptimal ovarian response
Objective. To determine a drug that is predominant in terms of pharmacoeconomic analysis for the treatment of infertility in patients with an insufficient ovarian response.Yagudina R.I., Kulikov A.Yu., Krylov V.A.
Material and methods. An information search for publications on the appropriate topic of this study was conducted in the PubMed, Medlink, and Cochrane Library databases. A total of 134 articles and abstracts were found. Two publications on an open prospective randomized controlled trial by Ferraretti et al. (2004) and an open randomized trial by Carone et al. (2012) were selected for further analysis. These articles are unique in the contents and design of the study.
Results. It was established that there was presently a limited number of studies available on the treatment of infertility in women with a suboptimal ovarian response, which had been conducted on a large sample of patients. An economic evaluation of the effectiveness of infertility treatment was made in patients with an insufficient ovarian response on the basis of effectiveness analysis, cost analysis, cost-effectiveness analysis, budget impact analysis, and sensitivity analysis. The compared alternatives were follitropin-alpha + lutropin–alpha/recombinant follicle-stimulating hormone (rFSH) + recombinant luteinizing hormone (rLH), follitropin-alpha/rFSH, and menotropin/human menopausal gonadotropin (hMG).
Conclusion. The results of pharmacoeconomic analysis have shown that follitropin-alpha + lutropin-alpha dominates in terms of cost-effectiveness analysis and leads to cost savings in the treatment of infertility in patients with a suboptimal ovarian response.
Keywords
pharmacoeconomics
cost analysis
cost-effectiveness analysis
budget impact analysis
menotropins
follitropin-alpha
follitropin-alpha + lutropin-alpha
References
1. Zegers-Hochschild F., Adamson G.D., de Mouzon J., Ishihara O., Mansour R., Nygren K. et al. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary on ART terminology, 2009. Fertil. Steril. 2009; 92(5): 1520-4.
2. Серов В.Н., Кира Е.Ф., ред. Гинекология. Руководство для врачей. М.: Литтерра; 2008: 778-80. [Serov V.N., Kira E.F., ed. Gynecology. A guide for doctors. Moscow: Litterra; 2008: 778-80. (in Russian)]
3. Сидорова И.С., Овсянникова Т.В., Макаров И.О., ред. Амбулаторно-поликлиническая помощь. Практическое руководство для врачей. М.: МЕДпресс-информ; 2009: 591-603. [Sidorova I.S., Ovsyannikova T.V., Makarov I.O., ed. Out-patient and polyclinic care. A practical guide for doctors. Мoscow: MEDpress-inform; 2009: 591-603. (in Russian)]
4. Здравоохранение в России. 2001: Стат. сб./ Росстат. М.; 2001. [Healthcare in Russia. 2001: Stat. col. / Rosstat. Moscow; 2001. (in Russian)]
5. Здравоохранение в России. 2013: Стат. сб./ Росстат. М.; 2013. [Healthcare in Russia. 2013: Stat. col. / Rosstat. Moscow; 2013. (in Russian)]
6. Здравоохранение в России. 2017: Стат. сб./ Росстат. М.; 2017. [Healthcare in Russia. 2017: Stat. col. / Rosstat. Moscow; 2017. (in Russian)]
7. Указ Президента РФ от 9 октября 2007 г. N 1351 „Об утверждении Концепции демографической политики Российской Федерации на период до 2025 года” (с изменениями и дополнениями). [Decree of the President of the Russian Federation of October 9, 2007 N 1351 “On the approval of the Concept of the demographic policy of the Russian Federation for the period until 2025” (with amendments and additions). (in Russian)]
8. Доклад Министра здравоохранения Российской Федерации Вероники Скворцовой в Государственной Думе в рамках «Правительственного часа». [Report of the Minister of Health of the Russian Federation Veronika Skvortsova in the State Duma within the framework of the “Government Hour”.(in Russian)]
9. Корсак В.С., Смирнова А.А., Шурыгина О.В. РАРЧ Отчет регистра ВРТ за 2015 год. В кн.: Материалы XXVII международной конференции РАРЧ «Репродуктивные технологии сегодня и завтра». г. Санкт-Петербург 6-9 сентября 2017 года. СПб.; 2017. [Korsak V.S., Smirnova A.A., Shuryigina O.V. RAHR Report of the Register of ART for the year 2015. In: Materials of the XXVII international conference of the RFCA “Reproductive technologies today and tomorrow”. St. Petersburg on September 6-9, 2017. St. Petersburg; 2017. (in Russian)]
10. Ferraretti A.P., La Marca A., Fauser B.C., Tarlatzis B.; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum. Reprod. 2011; 26(7): 1616-24.
11. Alviggi C., Andersen C.Y., Buehler K., Conforti A., De Placido G., Esteves S.C., Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil. Steril. 2016; 105(6): 1452-3.
12. Bühler K.F., Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case–control study. Gynecol. Endocrinol. 2012; 28(5): 345-50.
13. Alviggi C., Clarizia R., Pettersson K., Mollo A., Humaidan P., Strina I. et al. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod. Biomed. Online. 2009; 18: 9-14.
14. Lehert P., Kolibianakis E.M., Venetis C.A., Schertz J., Saunders H., Arriagada P. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod. Biol. Endocrinol. 2014, 12: 17.
15. Ferraretti A.P., Gianaroli L., Magli M.C., D’Angelo A., Farfalli V., Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil. Steril. 2004; 82(6): 1521-6.
16. Carone D., Caropreso C., Vitti A., Chiappetta R. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols. J. Endocrinol. Invest. 2012; 35(11): 996-1002.
17. Данные Федеральной службы государственной статистики. (по состоянию на 26.04.2018) [Data of the Federal State Statistics Service. (as of April 26, 2013) (in Russian)]
18. Sun W., Stegmann B.J., Henne W., Catherino W.H., Segars J.H. A new approach to ovarian reserve testing. Fertil. Steril. 2008; 90(6): 2196-202.
19. Petraglia F., Serour G.I., Chapron C. The changing prevalence of infertility. Int. J. Gynaecol. Obstet. 2013; 123(Suppl. 2): S4-8
20. Хабриев Р.У., Куликов А.Ю., Аринина Е.Е. Методологические основы фармакоэкономического анализа. М.: Медицина; 2011. 128с. [Habriev R.U., Kulikov A.Yu., Arinina E.E. Methodological bases of pharmacoeconomic analysis. Moscow: Meditsina; 2011. 128p. (in Russian)]
Received 06.04.2018
Accepted 20.04.2018
About the Authors
Roza I. Yagudina, Doctor of Philosophy, Professor, Head of the Department of Organization of Drug Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia. 127018, Russia, Moscow, Skladochnaya str. 1, bld. 17. E-mail: yagudina@inbox.ruAndrey Y. Kulikov, Doctor of Economics, Professor of the Department of Organization of Drug Supply and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia. 127018, Russia, Moscow, Skladochnaya str. 1, bld. 17. E-mail: 7677041@mail.ru
Vyacheslav A. Krylov, post-graduate student of the Department of Organization of Drug Supply and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia. 127018, Russia, Moscow, Skladochnaya str. 1, bld. 17. E-mail: v_a_ krylov@mail.ru
For citations: Yagudina R.I., Kulikov A.Yu., Krylov V.A. Pharmacoeconomic analysis of infertility treatment in women with a suboptimal ovarian response. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (6): 77-84. (in Russian)
https://dx.doi.org/10.18565/aig.2018.6.77-84
Similar Articles
